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Background: With many atypical antipsychotics now available in the market, it has become a common clinical
practice to switch between atypical agents as a means of achieving the best clinical outcomes. This study aimed to
examine the impact of switching from olanzapine to risperidone and vice versa on clinical status and tolerability
outcomes in outpatients with schizophrenia in a naturalistic setting.
Methods: W-SOHO was a 3-year observational study that involved over 17,000 outpatients with schizophrenia from
37 countries worldwide. The present post hoc study focused on the subgroup of patients who started taking
olanzapine at baseline and subsequently made the first switch to risperidone (n=162) and vice versa (n=136).
Clinical status was assessed at the visit when the first switch was made (i.e. before switching) and after switching.
Logistic regression models examined the impact of medication switch on tolerability outcomes, and linear
regression models assessed the association between medication switch and change in the Clinical Global
Impression-Schizophrenia (CGI-SCH) overall score or change in weight. In addition, Kaplan-Meier survival curves and
Cox-proportional hazards models were used to analyze the time to medication switch as well as time to relapse
(symptom worsening as assessed by the CGI-SCH scale or hospitalization).
Results: 48% and 39% of patients switching to olanzapine and risperidone, respectively, remained on the medication
without further switches (p=0.019). Patients switching to olanzapine were significantly less likely to experience relapse
(hazard ratio: 3.43, 95% CI: 1.43, 8.26), extrapyramidal symptoms (odds ratio [OR]: 4.02, 95% CI: 1.49, 10.89) and
amenorrhea/galactorrhea (OR: 8.99, 95% CI: 2.30, 35.13). No significant difference in weight change was, however, found
between the two groups. While the CGI-SCH overall score improved in both groups after switching, there was a
significantly greater change in those who switched to olanzapine (difference of 0.29 points, p=0.013).
Conclusion: Our study showed that patients who switched from risperidone to olanzapine were likely to experience a
more favorable treatment course than those who switched from olanzapine to risperidone. Given the nature of
observational study design and small sample size, additional studies are warranted.
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With many atypical antipsychotics now available in the
market, it has become a common clinical practice to
switch between atypical agents as a means of achieving
the best clinical outcomes [1]. It is, therefore, crucial for
clinicians and decision makers to understand the possible
benefits and risks associated with switching between
atypical agents. Because of the potential implications on
prevailing standards of clinical practice, the conse-
quences of switching between olanzapine and risperidone
are of particular interest as they are the two most com-
monly prescribed antipsychotics [2,3].
Some prior research has shown the clinical utility of
switching from olanzapine to risperidone or vice versa.
Ganguli et al. (2008) conducted an open-label trial to
evaluate the efficacy and safety of risperidone in patients
with schizophrenia who had been non-responsive or in-
tolerant to olanzapine. The results of the study showed
that switching from olanzapine to risperidone, regardless
of whether the switching was abrupt or gradual, was
associated with significant symptom improvement, espe-
cially in positive and anxiety symptoms, and was gener-
ally well tolerated. Clinical benefits of switching to
risperidone after insufficient response to olanzapine have
also been reported by Takahashi et al. (2006b) who fo-
cused on patients with first-episode schizophrenia. Con-
versely, in another open-label trial involving the same
type of patients, these authors found that non-
responders to risperidone treatment benefited from a
switch to olanzapine [4]. The benefit of switching from
risperidone to olanzapine was also reported in other
open-label trials involving a broader spectrum of
patients with schizophrenia [5,6]. While the experimen-
tal data from these open-label trials confirmed the bene-
fits of switching between risperidone and olanzapine,
patient behavior and outcomes are likely to differ in ac-
tual clinical settings. Moreover, except for one costing
study [1], there have been no direct comparisons be-
tween the switch from olanzapine to risperidone and the
switch from risperidone to olanzapine. Using a claims
database, Zhao et al. (2004) reported that patients who
switched from risperidone to olanzapine had a decrease
in total medical costs despite an increase in medication-
related costs, whereas those switching from olanzapine
to risperidone had no significant change in total health
care costs despite decreased medication-related costs.
Most patients with schizophrenia who change medica-
tion do so because they have severe disease that is not
fully responsive to the existing medication, so switching
to another medication is likely to show improvements.
Thus, the relative benefits of two medications can only
be fully understood by comparing the changes achieved
when switching from one medication to the other and
vice versa.To better understand the clinical implications of
switching between risperidone and olanzapine in the
‘real world’ setting, the present study conducted a post
hoc analysis using data accrued from the large naturalis-
tic 3-year W-SOHO (Worldwide-Schizophrenia Out-
patient Health Outcomes) study. The specific objectives
of the present analysis were two-fold: (1) to compare
clinical outcomes before and after switching from oral
risperidone to oral olanzapine as well as switching from
oral olanzapine to oral risperidone, respectively, and (2)
to compare the post-switch clinical outcomes between
the two groups.
Methods
Study design and patient sample
The Schizophrenia Outpatient Health Outcomes (SOHO)
study was a 3-year, international, prospective, observational
study primarily designed to assess the comparative costs
and outcomes associated with antipsychotic use in outpati-
ents initiating or changing antipsychotic medication for
schizophrenia (with an emphasis on olanzapine compared
with other antipsychotics). SOHO was conducted in 10
Western European countries (EU-SOHO) [7,8], and in 27
countries across 4 continents as the Intercontinental
SOHO (IC-SOHO) [9]. Data from all 37 participating
countries were pooled to produce the Worldwide-SOHO
(W-SOHO) dataset. A total of 17,384 patients were
included in W-SOHO, and the details of the study are
available elsewhere [10]. The study was carried out in ac-
cordance with the ethical standards of responsible local
committees and regulations of the participating countries
[7]. It was approved in all countries at the site, regional or
national level, depending on the countries’ regulations and
participating sites in each country. Patient consent fol-
lowed country regulations. All patients gave at least oral
informed consent and written informed consent was
obtained in Denmark, Italy, Portugal, Spain, Ireland, and
the UK.
Participating psychiatrists offered enrolment to adult
patients (at least 18 years of age) initiating or changing
antipsychotic medication for the treatment of schizo-
phrenia, who presented within the normal course of care
in the outpatient setting or in the hospital when admis-
sion was planned for the initiation or change of anti-
psychotic medication and discharge was planned within
2 weeks, and who were not participating in another inter-
ventional study. The diagnosis of schizophrenia was
made by the participating psychiatrists using standard
diagnostic criteria [Diagnostic and Statistical Manual of
Mental Disorders 4th ed [11] or International Classifica-
tion of Diseases 10th ed [12]]. Patient enrolment began in
September 2000 for EU-SOHO and in November 2000
for IC-SOHO; the last patient was enrolled in December
2001. The enrolment period was intentionally long to
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minimum number of patients was required per partici-
pating psychiatrist.
As the initial objective of SOHO was to compare the
outcomes of patients starting olanzapine with other anti-
psychotics, the study was designed to provide two pa-
tient cohorts of approximately equal size: (1) patients
starting olanzapine, and (2) patients starting any other
antipsychotic. This deliberate over-sampling of olanza-
pine patients was done to facilitate comparisons between
the two groups, in accordance with the primary object-
ive. Importantly, the antipsychotic treatment prescribed
to each patient was wholly based on the opinion of the
treating psychiatrist; patients were asked to participate
in the study after they had received their medication
prescription. In addition, patients were not required to
continue taking the medication initiated at baseline.
Changes in medication, dosing and concomitant medica-
tion were possible at any time as determined by the
treating psychiatrist.
Data collection for the study occurred at the baseline
visit and at follow-up visits (i.e. 3, 6, 12, 18, 24, 30 and
36 months post-baseline) within the normal course of
care. Socio-demographic data were recorded at the base-
line assessment. Clinical severity was assessed at each
visit using a scale based on the Clinical Global Impres-
sions Severity Scale – Schizophrenia version (CGI-SCH)
[13], which evaluates symptom severity across positive,
negative, depressive and cognitive sub-domains as well
as overall symptoms from 1 (normal, not ill) to 7
(among the most severely ill). Other information col-
lected at follow-up visits included clinical status (e.g.,
weights (kg), alcohol/substance abuse/dependency, suicide
attempts, occurrence of violent or aggressive behavior),
functional status (e.g., relationships, housing conditions,
work and social contacts), antipsychotic medication (drug
name, formulation, dosage and reasons for medication
change if applicable), concomitant medication (anticholi-
nergics, antidepressant, anxiolytics/hypnotics and mood
stabilizers), adverse events, quality of life, and health
service use.
Statistical analysis
Patients with no more than one missing visit (excluding
the last visit) were eligible for inclusion in the present
analysis (n=11,078, 64% of the baseline sample). For
patients with one missing visit, values from the previous
visit were carried forward to impute the values of the
missing visit. Of the 11,078 study completers, the
present study focused on the subgroup of patients who
started with olanzapine monotherapy and switched to
risperidone monotherapy (n=162) (termed as the ‘OLZ-
RIS’ group hereafter) or started with risperidone mono-
therapy and switched to olanzapine monotherapy(n=136) (termed as the ‘RIS-OLZ’ group hereafter) as
the first medication switch during follow-up.
Kaplan-Meier survival curves of the time to (second)
medication switch were plotted for each group (OLZ-
RIS and RIS-OLZ). The overall difference between sur-
vival curves was compared using the log-rank test.
Medication switch was defined as: (1) stopping the treat-
ment with or without replacing it with another anti-
psychotic; or (2) adding a new antipsychotic to the
treatment. Time to switch was also examined using a
Cox proportional hazards model, adjusting for patient
characteristics before switching.
The analysis focused on the following key outcomes:
change in CGI-SCH overall score; extrapyramidal symp-
toms (EPS); loss of libido; impotence/sexual dysfunction;
amenorrhea/galactorrhea; weight (kg) change; and time
to relapse. Outcomes before and after switching were
compared within each group using McNemar tests (for
categorical variables) and paired t-tests (for numerical
variables), except for time to relapse. Outcomes before
switching were assessed at the visit when the first switch
was made. Outcomes after switching were measured at
the visit when a further switching occurred or otherwise
at 36-months. Multivariate regression models (logistic or
linear regressions) were also used to examine the impact
of switching on these outcomes, adjusting for patient
characteristics.
Time to relapse was examined only among patients
who attained a CGI-SCH overall score of ≤3 (i.e. mildly
ill or less) after the first switch from olanzapine to ris-
peridone (or vice versa) but before a further switch was
made or before 36 months. Starting from this new “base-
line”, relapse was defined as an increase of at least 2
points on the GGI-SCH overall severity score from the
minimum score achieved by the patient during the
follow-up assessment (till a further switch occurred;
otherwise till 36-months), resulting in a rating of moder-
ately ill or worse (score ≥4), or having had a hospitalization
[14]. Of the 298 patients included, only 186 patients
met this criterion (n=98 in the OLZ-RIS group and
n=88 in the RIS-OLZ group). Time to relapse for the
OLZ-RIS and RIS-OLZ groups was estimated using
Kaplan-Meier survival curves, and also analyzed
using Cox-proportional hazards model controlling for
patient characteristics.
In all multivariate analyses (Cox, logistic, and linear
regressions), patient group (i.e. RIS-OLZ group or OLZ-
RIS group) served as the main explanatory variable while
adjusting for the influence of the following key covari-
ates: time of switch; age; gender; region; and CGI-SCH
overall score before switching. Corresponding tolerabil-
ity outcomes before switching were also included in the
analysis of post-switch tolerability outcomes. In addition,
other variables before switching were included in
Table 2 Patient characteristics before switching from
risperidone to olanzapine and from olanzapine to
risperidone
OLZ-RIS
(n=162)
RIS-OLZ
(n=136)
Age (years) a 37.2 ± 13.3 36.5 ± 12.5
Male (%)b 51.2 51.9
Age at first service contact for
schizophrenia (years)a
27.6 ± 10.3 27.9 ± 10.5
Duration of illness (years)a 9.7 ± 10.1 8.8 ± 8.9
CGI-SCH overalla 3.5 ± 1.2 3.6 ± 1.2
CGI-SCH positivea 3.0 ± 1.4 3.0 ± 1.4
CGI-SCH negativea 3.1 ± 1.3 3.2 ± 1.3
CGI-SCH cognitivea 2.8 ± 1.3 3.1 ± 1.3
CGI-SCH depressivea 2.7 ± 1.3 3.0 ± 1.4
Current alcohol abuse (%)b,* 5.0 1.5
Current substance abuse (%)b 2.5 3.7
Being hostile (%)b 9.9 11.0
Having a spouse/partner (%)b 30.4 24.2
Living independently (%)b 55.9 49.6
Being socially active (%)b 80.1 77.8
Being employed (%)b 29.8 25.2
a Data presented as mean (SD), t-test employed.
b Data presented as %, chi-test employed.
* Significant at p<0.05.
OLZ-RIS: Patients who switched from olanzapine to risperidone.
RIS-OLZ: Patients who switched from risperidone to olanzapine.
CGI-SCH: Clinical Global Impression-Schizophrenia.
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backward stepwise reduction technique: time since first
service contact for schizophrenia; current alcohol abuse/
dependency; current substance abuse/dependency; hos-
tility; having a relationship; having paid employment; liv-
ing independently; being socially active; and taking
concomitant medications (anticholinergics, antidepres-
sant, anxiolytics/hypnotics, and mood stabilizers).
All analyses were also repeated in a sensitivity analysis,
which defined the (second) medication switch as stop-
ping the treatment with or without replacing it with an-
other antipsychotic. That is, in this sensitivity analysis,
adding a new antipsychotic to the treatment was not
considered as a switching.
Results
Of the 11,078 study completers, 6,412 patients started
with either olanzapine monotherapy (n=4,736) or risper-
idone monotherapy (n=1,676) at baseline. Of these, a
total of 2,493 patients (38.9%) switched their baseline
medications over the 3-year follow-up: 1726 (36.4%)
among the patients initiated on olanzapine monotherapy
and 767 (45.8%) among the patients initiated on risperi-
done monotherapy. The present study, however, only
included a subsample of patients who switched to either
olanzapine monotherapy (n=136) or risperidone mono-
therapy (n=162) as their first medication switch during
follow-up. The most common reason for discontinuation
was lack of efficacy in both groups (Table 1). The mean
dose for olanzapine was 10.1 (SD: 5.3) before switching
and that for risperidone was 4.7 (SD: 3.0).
The demographics and clinical characteristics of the
patients before switching are reported for both groups in
Table 2. The patient characteristics were similar between
the two groups, except that patients in the OLZ-RIS
group were significantly more likely to be alcohol
dependent/abusive before switching, compared with
those in the RIS-OLZ group.Table 1 Medication dose and reasons for discontinuation
before and after switching
Before switching After switching
OLZ-RIS
(n=162)
RIS-OLZ
(n=136)
OLZ-RIS
(n=162)
RIS-OLZ
(n=136)
Dose (Mean ± SD) 10.1±5.3 4.7±3.0 4.6±3.2 10.9±5.9
Reason for discontinuation
(%)a
Lack of efficacy 41.3 59.1 36.0 34.0
Intolerability 29.7 31.8 15.7 20.0
Lack of compliance 19.4 23.5 19.1 16.0
Patient request 34.8 28.8 19.1 26.0
aMore than one reason allowed.
OLZ-RIS: Patients who switched from olanzapine to risperidone.
RIS-OLZ: Patients who switched from risperidone to olanzapine.Figure 1 shows the Kaplan-Meier curves for the rate of
(second) medication switch during follow-up for the
OLZ-RIS and RIS-OLZ groups. Patients who switched
to olanzapine were more likely to remain on this medi-
cation longer (47.6% and 38.9% of patients switching to
olanzapine and risperidone, respectively, made no fur-
ther switches, p=0.019). The Cox-regression, which
adjusted for differences in patient characteristics before
switching, found an increased risk of medication switch
in patients who switched to risperidone, compared with
those who switched to olanzapine, although this was not
statistically significant at the 0.05 level (HR= 1.44; 95%
CI=0.97, 2.12; p=0.070).
Patients who started treatment with either olanzapine or
risperidone experienced symptom improvement on their
initial medication (as assessed by the CGI-SCH overall
score), and a further improvement after the medication
switch (Table 2). Patients in the RIS-OLZ group achieved a
mean reduction in CGI-SCH overall score from baseline of
0.71 points (SD: 1.20) and 1.46 points (SD: 1.29) before and
after the medication switch, respectively. Likewise, patients
in the OLZ-RIS group achieved a mean reduction from
baseline of 0.75 points (SD: 1.05) and 1.15 points (SD: 1.12)
before and after the medication switch, respectively.
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Figure 1 Kaplan-Meier estimates of time to (second) medication switch. Figure 1 shows the Kaplan-Meier curves for the rate of (second)
medication switch during follow-up for the OLZ-RIS and RIS-OLZ groups.
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switching, tolerability outcomes differed between the
two groups (Table 3). Patients who switched to olanza-
pine experienced significant improvements after switch-
ing in all tolerability outcomes except weight change,
which did not differ significantly between before and
after switching. Patients who switched to risperidone did
not make improvements in any of the tolerability out-
comes after switching and experienced a worsening in
amenorrhea/galactorrhea. In addition, the Kaplan-Meier
curves showed that 85.5% of patients in the RIS-OLZ
group did not experience relapse during follow-up, while
only 63.9% of patients in the OLZ-RIS group did not re-
lapse during follow-up (p=0.015) among patients who
attained a CGI-SCH overall score ≤3 (i.e. mildly ill or
less) (Figure 2). Consistent with this, the Cox-regression
model showed that patients who switched to risperidone
were more likely to experience relapse during follow-upTable 3 Change in clinical status before and after switching
B
OLZ-RIS (n
Change in CGI-overall score from baselinea (Mean ± SD) −0.75±1
EPSb (%) 15.2
Loss of libidob (%) 28.8
Impotence/sexual dysfunctionb (%) 18.9
Amenorrhoea/galactorrheaa (%) 12.0
Change in weight (kg) from baselinec (Mean ± SD) 3.14±6.
aThe difference between before and after switching was significant in both groups
bThe difference between before and after switching was significant only in patients
cThe difference between before and after switching was not significant in either gro
OLZ-RIS: Patients who switched from olanzapine to risperidone.
RIS-OLZ: Patients who switched from risperidone to olanzapine.
EPS: Extrapyramidal Symptom.(HR=3.43; 95% CI= 1.43, 8.26; p=0.006), compared with
those who switched to olanzapine.
Table 4 summarizes the results of the regression analyses.
Linear regression showed improvements in the CGI-SCH
overall score after switching in both groups, and that those
who switched to olanzapine had a further 0.29 point reduc-
tion in this score (p=0.013). Logistic regression analyses
also showed more favorable outcomes in the RIS-OLZ
group after switching, compared with the OLZ-RIS group:
patients who switched to risperidone were more likely to
have EPS (OR=4.02; 95% CI=1.49, 10.89; p=0.006) and
amenorrhea/galactorrhea (OR=8.99; 95% CI=2.30, 35.13;
p=0.002). There were no statistically significant differences
between the two groups after switching for the other toler-
ability outcomes (loss of libido, impotence/sexual dysfunc-
tion and weight change).
The results of the sensitivity analysis (where adding a
new antipsychotic to the treatment was not consideredefore switching After switching
=162) RIS-OLZ (n=136) OLZ-RIS (n=162) RIS-OLZ (n=136)
.05 −0.71±1.20 −1.15±1.12 −1.46±1.29
28.4 15.2 9.0
37.8 31.3 26.7
29.3 22.0 19.6
12.6 17.7 5.9
05 1.43±4.21 4.11±8.39 1.95±8.90
(p<0.05).
who switched to olanzapine (i.e., the RIS-OLZ group).
up.
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Figure 2 Kaplan-Meier estimates of time to relapse. Figure 2 shows the Kaplan-Meier curves for the rate of relapse during follow-up for the
OLZ-RIS and RIS-OLZ groups. This analysis was confined to those patients who attained a CGI-SCH overall score of ≤3 (i.e. mildly ill or less) after
the first switch from olanzapine to risperidone (or vice versa) but before a further switch was made or before 36 months (n=98 in the OLZ-RIS
group and n=88 in the RIS-OLZ group).
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these findings (results available upon request).
Discussion
To our knowledge, this is the first study that has
assessed and compared clinical outcomes (effectiveness/
tolerability) of switching from olanzapine to risperidoneTable 4 The impact on clinical outcomes of switching to
risperidone, compared with switching to olanzapine
Estimate 95% confidence
interval
P-values
Cox regression Hazard ratioa
Medication switch 1.44 0.97, 2.12 0.070
Relapse 3.43 1.43, 8.26 0.006
Linear regression Coefficientb
Change in CGI-SCH overall
score before and after
switching
0.29 0.06, 0.52 0.013
Change in weight (kg) before
and after switching
0.22 −1.37, 1.81 0.785
Logistic regression Odds ratioc
EPS 4.02 1.49, 10.89 0.006
Loss of Libido 1.77 0.93, 3.37 0.083
Impotence/sexual dysfunction 1.93 0.95, 3.94 0.070
Amenorrhea/galactorrhea 8.99 2.30, 35.13 0.002
aA hazard ratio of more than 1 indicates an increased risk of medication
switch or relapse, compared with patients switched to olanzapine.
bLinear regression modeled a change in CGI-SCH overall score (or weight)
before and after switching. Coefficients indicate an estimated difference in the
change, compared with patients switched to olanzapine.
cAn odds ratio of more than 1 indicates an increased likelihood of having
tolerability outcomes compared with patients switched to olanzapine.and vice versa in the usual course of schizophrenia care.
Our results showed that patients who were treated with
risperidone and subsequently switched to olanzapine for
clinical reasons experienced a more favorable treatment
course than patients who were treated with olanzapine
and subsequently switched to risperidone. Patients who
switched to olanzapine experienced significant improve-
ments in symptom control (as assessed by the CGI-SCH
overall score) and in all tolerability outcomes (EPS, loss
of libido, impotence/sexual dysfunction, and amenorrhea/
galactorrhea) except for weight gain. On the other hand,
patients who initiated with olanzapine and switched to ris-
peridone did not experience improvements in any of the
tolerability outcomes, although they experienced signifi-
cant improvements in symptom control. The differential
effect between the two groups remained even when the
patient characteristics before switching were taken into
account in multivariate analyses. Patients who switched to
olanzapine were more likely to improve in symptom
control and less likely to experience relapse, EPS and
amenorrhea/galactorrhea, compared with those who
switched to risperidone.
Consistent with previous research [5,15], patients experi-
enced symptom improvement after medication switch in
both the RIS-OLZ and OLZ-RIS groups. However, symp-
tom improvement was greater in those who switched
from risperidone to olanzapine. This finding was par-
tially in agreement with recent results from the Clinical
Antipsychotic Trials for Intervention Effectiveness study
(CATIE) [16]. In phase 2T of the CATIE study (conducted
in patients who primarily experienced intolerability to
their previous antipsychotic), the olanzapine group
achieved greater improvement than the risperidone group
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and Negative Syndrome Scale (PANSS). However, there
were no differences between groups in negative and
overall symptoms. Data from other head-to-head
trials are available [17], but they do not suggest that
one drug is clearly more effective than the other in
symptom control. However, consistent with our findings,
olanzapine appears to be superior to risperidone in
relapse prevention, EPS and reproductive adverse
events [17].
Relapse prevention is a primary goal in the long-term
treatment of schizophrenia. Surprisingly, however, there
is only limited information on the comparison between
risperidone and olanzapine. Nevertheless, this small
body of literature also reports a lower risk of relapse in
patients treated with olanzapine compared with those
treated with risperidone [14,18,19].
EPS are common adverse events during treatment
with antipsychotics, especially for conventional agents.
They are the most common reason for non-adherence
with antipsychotic medication, leading to treatment fail-
ures, relapses, poorer long-term outcomes and prevent-
able economic costs [20-22]. Atypical antipsychotics
have a lower risk of EPS than conventional antipsycho-
tics, and this is a considerable asset from a tolerability
and safety point of view [23]. However, the risk of EPS
varies among atypical antipsychotics and dose-dependent
increases in EPS have been observed with risperidone
[24]. Several studies have provided the evidence that
patients treated with olanzapine may have a lower risk of
EPS than patients treated with risperidone [25]. Previous
SOHO publications also showed a lower risk of EPS with
olanzapine compared with risperidone [26]. Moreover, a
UK population-based study reported reduced use of anti-
parkinsonian drugs (treatment for EPS) in patients who
switched from conventional agents to olanzapine, but
not in those who switched to risperidone [20]. A
reduced use of antiparkinsonian drugs was also
observed in patients who switched from risperidone
to olanzapine, but not in those switched from olanza-
pine from risperidone [1]. Lowering the risk of EPS is
crucial in the management of schizophrenia, given
their clinical and economic implications.
Consistent with previous studies [27,28], our study
demonstrated a lower risk of amenorrhea/galactorrhea
with olanzapine compared with risperidone. One pos-
sible reason for this may be the potent effect of risperi-
done on prolactin elevation, although plasma prolactin
concentrations were not measured in the SOHO study.
Prolactin elevation is a well-known adverse event of con-
ventional antipsychotics and of some atypical antipsy-
chotics such as risperidone [29], although treatment
with olanzapine may also elevate prolactin level and the
elevation may persist during chronic administration [30].An increase in prolactin levels can cause amenorrhea,
galactorrhea and other sexual disturbances [29,31]. A
number of studies have shown that the risk of prolac-
tin elevation with risperidone is similar to or greater
than that of conventional antipsychotics [29,31,32].
The switching study from olanzapine to risperidone by
Takahashi and colleagues also reported a significant in-
crease in plasma prolactin concentrations after the
medication switch [33]. However, the findings of a re-
cent study in patients with first episode psychosis indi-
cated that such reproductive adverse events can occur
even when prolactin levels are normal [34]. While the
mechanisms underlying such reproductive adverse events
in antipsychotic-treated patients are not yet clearly
understood, it is well known that hyperprolactinemia
can cause amenorrhea and galactorrhea.
In addition, weight gain has been commonly reported
during treatment with most atypical antipsychotics, in-
cluding olanzapine and risperidone [29]. However, our
study did not find any significant differences in weight
change before and after medication switch between the
two groups (i.e. RIS-OLZ and OLZ-RIS groups). Not-
ably, however, patients who were on olanzapine at base-
line gained an average of 3.14 kg before switching to
risperidone. In comparison, those who were initially on
risperidone gained an average of 1.43 kg before switch-
ing to olanzapine.
The results of this study also confirmed that medica-
tion switch is a common practice in the management of
schizophrenia [29]. More than one in three outpatients
with schizophrenia who initiated treatment with either
olanzapine or risperidone switched antipsychotic medi-
cation at least once during the 3-year follow-up in the
normal course of care. In addition, more than half of the
switchers also made subsequent switches (52.4% for
patients who switched to olanzapine and 61.1% for
patients who switched to risperidone). While medica-
tion switch constituted a logical and common treatment
strategy for patients who did not respond adequately to
the prescribed antipsychotic treatment or could not tol-
erate treatment-emergent adverse events, it may not al-
ways result in improvement, as indicated in our study.
Although the results of our study confirmed that
switching to olanzapine would be of benefit to patients
who failed treatment with risperidone, the converse was
not confirmed.
Our results need to be interpreted in the context of
the following study limitations. Firstly, the W-SOHO
study was originally designed and powered to compare
clinical and economic outcomes between olanzapine and
other antipsychotics. Comparison of the impact of
switching antipsychotics between olanzapine and risperi-
done was a post hoc analysis and, consequently, the rele-
vant subgroup sample size was small. This, in turn,
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study sample was initially drawn from 11,078 patients,
who completed the study and had no more than one
missing visits during follow-up (i.e., 64% of the baseline
sample). Although the retention rate of 64% was rela-
tively high given the study duration of three years and
thereby the same size of study completers was still very
large, the clinical prognosis could differ between study
completers and those who were not. It is, however, un-
clear whether the inclusion of study completers only dis-
proportionally influenced the outcomes of the OLZ-RIS
and RIS-OLS groups. Thirdly, as the outcome assess-
ments were not performed blind, we cannot exclude the
possibility that the treating psychiatrists were likely to
evaluate patients more favorably after the switch. Never-
theless, this bias is unlikely to differ between medica-
tions. In addition, as the clinical outcomes were assessed
by the treating psychiatrists, the assessment could have
been subjective and influenced by their prior knowledge
and expectations (i.e., observer bias). This could be of
particular concern in the absence of blinding if more
favourable assessments were made towards their pre-
ferred treatment. Notably however, a previous study [35]
explicitly investigated the observer bias in SOHO by
comparing patient- and investigator-reported outcomes,
and found no such bias. Fourthly, although our find-
ings were adjusted for pre-switch clinical and demo-
graphic characteristics of patients when comparing the
impact of switching on clinical outcomes, there could
be unobserved differences between the treatment
groups, which may confound our results. Finally, for
patients who switched medication between visits, we
assumed that clinical status was similar to that at the
visit before the switch.
Conclusion
The results of the present study demonstrate that there
is a more favorable treatment course in patients with
schizophrenia who switched from risperidone to olanza-
pine. They were significantly more likely to remain on
the medication longer and improve in symptom control,
and significantly less likely to experience relapse, EPS
and amenorrhea/galactorrhea, compared with those
switched from olanzapine to risperidone. This suggests
that while olanzapine can be an effective treatment op-
tion for patients requiring a switch from risperidone,
treatment with risperidone may have limited benefits for
those requiring a switch from olanzapine. Nevertheless,
given the nature of observational study design and small
sample size, additional studies are warranted.
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